Blend Labs, Inc.

BLND

NYSE; business equipment; SIC 7370, Services-Computer Programming, Data Processing, Etc.; CIK 0001855747

D/E

on the D/E boundary of 495 graded peers in business equipm...

rank 396 of 495; percentile 80.0; sampling error 2.2 points; lower is stronger



D/E, the sloth



Scoreboard	
Profitability	C percentile 52.6
Solvency	D percentile 74.7
Growth and financing	C/D percentile 62.1
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $170.0M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	distress; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 16, 2026 240 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$1.09 2026-11-10; market equity $259.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 16, 2026

Blend (NYSE: BLND) is on a mission to transform the financial services industry by making the process of obtaining a loan or opening an account as seamless and intuitive as modern e-commerce. Today's consumers expect simplicity, hyper-personalization, and speed across every banking and lending interaction. Our platform brings together the data, technology, and AI-powered architecture needed to streamline and personalize every step of origination.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 52.6						
Gross profitability	53.6%	28.7%		14.0	552	2025-12-31
Return on invested capital	not computable	11.4%				
prior invested-capital observation is 92 days earlier						
Accruals ratio	not computable	(7.3%)				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

prior assets observation is 92 days earlier					
Gross margin stability, five years	14.2 pts	2.3 pts	91.2	423	2025-12-31
Solvency, sleeve percentile 74.7					
Twelve-month failure probability	2.06%	0.05%	93.3	105	2026-09-30
Altman Z double-prime	(26.07)	2.21	92.0	562	2025-12-31
Net debt to EBITDA	not computable	1.08x			
EBITDA must exceed $100,000					
Interest coverage	not computable	3.77x			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.48x	2.01x	39.0	660	2025-12-31
Growth and financing, sleeve percentile 62.1					
Revenue growth, three-year compound	(19.3%)	6.5%	93.6	532	2025-12-31
Free cash flow growth, three-year compound	not computable	18.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	15.1%			
prior working capital is not one fiscal year earlier					
Asset growth, three years	not computable	5.2%			
four consecutive annual observations are required					
Net share issuance, one year	(0.8%)	0.5%	30.6	406	2025-12-31

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Distress	CHS probability 2.055370%; universe top-decile threshold 1.836407%
Fortress balance sheet	cash minus debt is 43,578,000 USD; Altman Z is not used

Among 495 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
391	Thermo Fisher Scientific Inc. (TMO)	78.9	D/E	
392	Clarivate plc (CLVT)	79.1	D/E	
393	GoDaddy Inc. (GDDY)	79.4	D/E	
394	Definitive Healthcare Corp. (DH)	79.6	D/E	fortress balance sheet
395	Maxlinear, Inc. (MXL)	79.8	D/E	
396	Blend Labs, Inc. (BLND)	80.0	D/E	distress, fortress balance sheet
397	Creative Realities, Inc. (CREX)	80.2	D/E	late filer
398	Progress Software Corp. (PRGS)	80.4	D/E	
399	ZoomInfo Technologies Inc. (GTM)	80.6	D/E	
400	Synaptics Inc. (SYNA)	80.8	D/E	
401	Quanterix Corp. (QTRX)	81.0	D/E	late filer, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-10 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(68.9%)	(2.0%)	7
Distance from 52-week high	(67.7%)	(34.4%)	15
EBIT to enterprise value	(9.2%)	1.7%	16
Free cash flow yield	(0.03%)	2.9%	25
Book value to price	(0.30)	0.28	3
Sales to price	0.48	0.32	61
Composite equity issuance, five years	not computable	4.3%	
Relative strength against the sector, log excess return	(1.44)	(0.29)	7

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$20.7M
Operating cash flow, four quarters	$17.7M
Months of runway	not finite
Days since last periodic filing	6 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$1.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$91.2M	2025-12-31	2026-03-16	10-K	26-000016
2	assets	us-gaap:Assets	$170.0M	2025-12-31	2026-03-16	10-K	26-000016
3	operating income	us-gaap:OperatingIncomeLoss	-$21.7M	2025-12-31	2026-03-16	10-K	26-000016
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$878,000	2025-12-31	2026-03-16	10-K	26-000016
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$249,000	2025-12-31	2026-03-16	10-K	26-000016
6	total debt	us-gaap:LongTermDebt	$0	2025-12-31	2026-03-16	10-K	26-000016
7	book equity	us-gaap:StockholdersEquity	-$30.5M	2025-12-31	2026-03-16	10-K	26-000016
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$43.6M	2025-12-31	2026-03-16	10-K	26-000016
9	total debt	us-gaap:LongTermDebt	$0	2025-09-30	2026-03-16	10-K	26-000016
10	book equity	us-gaap:StockholdersEquity	-$13.4M	2025-09-30	2026-03-16	10-K	26-000016
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$55.0M	2025-09-30	2026-03-16	10-K	26-000016
12	net income	us-gaap:NetIncomeLoss	-$6.8M	2025-12-31	2026-03-16	10-K	26-000016
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$11.5M	2025-12-31	2026-03-16	10-K	26-000016
14	assets	us-gaap:Assets	$188.6M	2025-09-30	2026-03-16	10-K	26-000016
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$123.6M	2025-12-31	2026-03-16	10-K	26-000016
16	gross profit	us-gaap:GrossProfit	$83.2M	2024-12-31	2026-03-16	10-K	26-000016
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$115.8M	2024-12-31	2026-03-16	10-K	26-000016
18	gross profit	us-gaap:GrossProfit	$76.5M	2023-12-31	2026-03-16	10-K	26-000016

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$109.5M	2023-12-31	2026-03-16	10-K	26-000016
20	gross profit	us-gaap:GrossProfit	$89.7M	2022-12-31	2025-03-13	10-K	25-000017
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$235.2M	2022-12-31	2025-03-13	10-K	25-000017
22	gross profit	us-gaap:GrossProfit	$116.0M	2021-12-31	2024-03-14	10-K	24-000015
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$234.5M	2021-12-31	2024-03-14	10-K	24-000015
24	current assets	us-gaap:AssetsCurrent	$97.9M	2025-12-31	2026-03-16	10-K	26-000016
25	current liabilities	us-gaap:LiabilitiesCurrent	$39.5M	2025-12-31	2026-03-16	10-K	26-000016
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.4B	2025-12-31	2026-03-16	10-K	26-000016
27	liabilities	us-gaap:Liabilities	$41.0M	2025-12-31	2026-03-16	10-K	26-000016
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$3.3M	2025-12-31	2026-03-16	10-K	26-000016
29	operating income	us-gaap:OperatingIncomeLoss	-$143.6M	2023-12-31	2026-03-16	10-K	26-000016
30	interest expense	us-gaap:InterestExpense	$30.8M	2023-12-31	2024-03-14	10-K	24-000015
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$11.6M	2025-12-31	2026-03-16	10-K	26-000016
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$13.0M	2024-12-31	2026-03-16	10-K	26-000016
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$9.7M	2024-12-31	2026-03-16	10-K	26-000016
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$127.6M	2023-12-31	2026-03-16	10-K	26-000016
35	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$35,000	2023-12-31	2026-03-16	10-K	26-000016
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$190.4M	2022-12-31	2025-03-13	10-K	25-000017
37	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$2.1M	2022-12-31	2025-03-13	10-K	25-000017
38	assets	us-gaap:Assets	$182.2M	2025-06-30	2026-03-16	10-K	26-000016
39	assets	us-gaap:Assets	$187.5M	2025-03-31	2026-03-16	10-K	26-000016
40	shares outstanding	us-gaap:CommonStockSharesOutstanding	256,043,000	2025-12-31	2026-03-16	10-K	26-000016
41	shares outstanding	us-gaap:CommonStockSharesOutstanding	258,173,000	2024-12-31	2026-03-16	10-K	26-000016

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.